Comparative Pharmacology
Head-to-head clinical analysis: ACHROMYCIN versus OXYTETRACYCLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACHROMYCIN versus OXYTETRACYCLINE HYDROCHLORIDE.
ACHROMYCIN vs OXYTETRACYCLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
Oxytetracycline binds reversibly to the 30S ribosomal subunit, inhibiting protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.
250-500 mg orally every 6 hours or 1-2 g/day divided every 12 hours intravenously.
None Documented
None Documented
6-12 hours; prolonged to 48-72 hours in severe renal impairment
6-10 hours (prolonged to 48-100 hours in renal impairment; consider dose adjustment in CrCl <50 mL/min)
Renal (60-80% unchanged via glomerular filtration); biliary/fecal (10-20%)
Renal (60-70% unchanged by glomerular filtration); biliary/fecal (20-35%)
Category C
Category D/X
Tetracycline Antibiotic
Tetracycline Antibiotic